A real-world disproportionality analysis of sacubitril/valsartan: data mining of the FDA adverse event reporting system

PurposeSacubitril/valsartan is extensively used in heart failure; however, there are few long-term safety studies of it in a wide range of populations. The aim of this study was to evaluate sacubitril/valsartan-induced adverse events (AEs) through data mining of the U.S. Food and Drug Administration...

Full description

Bibliographic Details
Published in:	Frontiers in Pharmacology
Main Authors:	Yiwen Wang, Xuna Liu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-08-01
Subjects:	sacubitril/valsartan adverse event data mining FAERS database pharmacovigilance
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1392263/full

Similar Items

A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS)
by: Ning Wang, et al.
Published: (2024-12-01)

Subgroup disproportionality analysis of dementia-related adverse events with sacubitril/valsartan across geographical regions
by: Seong Kyung Kim, et al.
Published: (2024-09-01)

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
by: Chang-Zhu He, et al.
Published: (2025-03-01)

A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system
by: Mingdi Liu, et al.
Published: (2024-01-01)

A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system
by: Bin Zhao, et al.
Published: (2024-03-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib
by: Yu Lin, et al.
Published: (2024-03-01)

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
by: Shiyi Wang, et al.
Published: (2025-02-01)

A disproportionality analysis of FDA adverse event reporting system events for misoprostol
by: Li Yang, et al.
Published: (2025-01-01)

Osimertinib-related myotoxicity: a disproportionality analysis of the FDA adverse event reporting system
by: Yaqian Tan, et al.
Published: (2025-08-01)

Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database
by: Shan Lin, et al.
Published: (2024-10-01)

A real-world disproportionality analysis of ripretinib data mining of the public version of FDA adverse event reporting system
by: Yingkai Feng, et al.
Published: (2025-03-01)

A real-world disproportionality analysis of cyclosporine from the FDA Adverse Event Reporting System (FAERS) database
by: Shichao Cui, et al.
Published: (2024-07-01)

Arrhythmic events pertinent with antidepressants: a Bayesian disproportional analysis mining the FDA Adverse Event Reporting System database
by: Shan Cao, et al.
Published: (2025-09-01)

Disproportionality analysis and risk factor assessment of drug-associated thyroid dysfunction adverse events: a study based on the FAERS database
by: Zhifang Wang, et al.
Published: (2025-07-01)

Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system
by: Yanjun Lu, et al.
Published: (2024-12-01)

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01)

Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database
by: Jinfeng Zhu, et al.
Published: (2024-07-01)

Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
by: Dan Zhao, et al.
Published: (2024-05-01)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
by: Yamin Shu, et al.
Published: (2023-05-01)

Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)
by: Ming-Tao Wen, et al.
Published: (2024-08-01)

Tirzepatide safety in type 2 diabetes: a disproportionality analysis of adverse events using the FDA FAERS database
by: Zhenpo Zhang, et al.
Published: (2025-07-01)

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
by: Yan Wu, et al.
Published: (2023-08-01)

A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system
by: Dan Chen, et al.
Published: (2025-08-01)

Expert Opinion on the Role of Sacubitril/Valsartan in the Management of Hypertension in India
by: Uday M. Jadhav, et al.
Published: (2024-11-01)

A real-world pharmacovigilance analysis of omadacycline in FDA adverse event reporting system (FAERS) database
by: Xueping Shi, et al.
Published: (2025-04-01)

Disproportionality analysis of adverse events associated with ipilimumab and nivolumab combination therapy based on FAERS database
by: Xianyu Dai, et al.
Published: (2025-07-01)

Ophthalmic corticosteroids-related adverse events: the FDA adverse event reporting system (FAERS) database pharmacovigilance study
by: Chengzhi Liu, et al.
Published: (2024-12-01)

Mining and analysis of adverse event signals of isotretinoin based on the real-world data of FAERS database
by: Liu Yang, et al.
Published: (2025-10-01)

Drug-induced heart failure: a real-world pharmacovigilance study using the FDA adverse event reporting system database
by: Youqi Huang, et al.
Published: (2025-01-01)

A real-world pharmacovigilance study of lorazepam based on the FDA adverse event reporting system database
by: Chunyue Fang, et al.
Published: (2025-06-01)

A real-world pharmacovigilance study of netarsudil based on the FDA adverse event reporting system (FAERS)
by: Xiaomei Xiong, et al.
Published: (2025-04-01)

Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Qi Song, et al.
Published: (2025-06-01)

Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
by: David Carballo, et al.
Published: (2020-06-01)

What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies
by: Hisham A. Badreldin, et al.
Published: (2022-02-01)

Post-marketing safety of lorlatinib: a real-world study based on the FDA adverse event reporting system
by: Huqun Li, et al.
Published: (2024-06-01)

ΔRDW Could Predict Major Adverse Cardiovascular Events in Patients with Heart Failure with Reduced Ejection Fraction After Sacubitril/Valsartan Treatment
by: Wang J, et al.
Published: (2023-12-01)

Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system
by: Chengyu Zhu, et al.
Published: (2025-03-01)

Sacubitril/Valsartan Ameliorates Crizotinib-Induced Cardiotoxicity in Mice
by: Lijun Cheng, et al.
Published: (2023-07-01)

Detection of muscular system adverse reaction signals in sacubitril/valsartan treatment combined with statins
by: Fukun Zhao, et al.
Published: (2024-07-01)

Safety assessment of rosuvastatin-fenofibrate combination in the treatment of hyperlipidemia based on FDA’s adverse event reporting system database
by: Qun Li, et al.
Published: (2025-02-01)